## Anne C Bay-Jensen

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1414595/anne-c-bay-jensen-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186 62 4,957 40 h-index g-index citations papers 5,891 5.63 193 3.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
186	Blood and urine biomarkers in osteoarthritis - an update on cartilage associated type II collagen and aggrecan markers. <i>Current Opinion in Rheumatology</i> , <b>2022</b> , 34, 54-60	5.3	2
185	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2) Rheumatology and Therapy, 2022, 1	4.4	0
184	Osteoarthritis endotype discovery via clustering of biochemical marker data <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	4
183	Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study. <i>Osteoarthritis and Cartilage</i> , <b>2021</b> ,	6.2	2
182	The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFITreatment in Crohnß Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 59-66	3	4
181	Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis. <i>Scientific Reports</i> , <b>2021</b> , 11, 6583	4.9	4
180	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e175-e184	14.2	3
179	A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. <i>Journal of Orthopaedics and Traumatology</i> , <b>2021</b> , 22, 10	5	6
178	Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. <i>Rheumatology International</i> , <b>2021</b> , 41, 1065-1077	3.6	2
177	Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?. <i>Expert Review of Proteomics</i> , <b>2021</b> , 18, 159-175	4.2	1
176	Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum. <i>Osteoarthritis and Cartilage Open</i> , <b>2021</b> , 3, 100162	1.5	1
175	A case report of pregnancy in untreated alkaptonuria - Focus on urinary tissue remodelling markers. <i>Molecular Genetics and Metabolism Reports</i> , <b>2021</b> , 27, 100766	1.8	
174	Are fatty acids associated with disease activity and biomarkers in patients with psoriatic arthritis? Data from a multicenter clinical trial. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	O
173	Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102706	13.6	7
172	Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 13	5.7	2
171	Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102760	13.6	1
170	Association between Markers of Synovial Inflammation, Matrix Turnover and Symptoms in Knee Osteoarthritis: A Cross-Sectional Study. <i>Cells</i> , <b>2021</b> , 10,	7.9	1

## (2020-2021)

169	Intermittent Dynamic Compression Confers Anabolic Effects in Articular Cartilage. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 7469	2.6	1
168	A Serological Type II Collagen Neoepitope Biomarker Reflects Cartilage Breakdown in Patients with Osteoarthritis. <i>Osteoarthritis and Cartilage Open</i> , <b>2021</b> , 3, 100207	1.5	1
167	Considerations for understanding protein measurements: Identification of formation, degradation and more pathological relevant epitopes. <i>Clinical Biochemistry</i> , <b>2021</b> , 97, 11-24	3.5	1
166	Enzymatic cross-linking of collagens in organ fibrosis - resolution and assessment. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 1049-1064	3.8	4
165	A matrix metalloproteinase-generated neoepitope of CRP can identify knee and multi-joint inflammation in osteoarthritis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 226	5.7	1
164	The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment <i>Scientific Reports</i> , <b>2021</b> , 11, 24285	4.9	O
163	The acute and long-term impact of physical activity on biochemical markers and MRI measures in osteoarthritisPerspectives for clinical osteoarthritis research. <i>Translational Sports Medicine</i> , <b>2020</b> , 3, 384-394	1.3	3
162	Characterization of the interleukin-17 effect on articular cartilage in a translational model: an explorative study. <i>BMC Rheumatology</i> , <b>2020</b> , 4, 30	2.9	7
161	Serum Biomarkers for Connective Tissue and Basement Membrane Remodeling are Associated with Vertebral Endplate Bone Marrow Lesions as Seen on MRI (Modic Changes). <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
160	Evaluation of serum ARGS neoepitope as an osteoarthritis biomarker using a standardized model for exercise-induced cartilage extra cellular matrix turnover. <i>Osteoarthritis and Cartilage Open</i> , <b>2020</b> , 2, 100060	1.5	3
159	Serological CTX-II does not measure the same as urinary CTX-II. <i>Osteoarthritis and Cartilage Open</i> , <b>2020</b> , 2, 100082	1.5	1
158	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , <b>2020</b> , 23, 532-539	2.3	7
157	Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo. <i>Scientific Reports</i> , <b>2020</b> , 10, 6011	4.9	13
156	Type III, IV, and VI Collagens Turnover in Systemic Sclerosis - a Longitudinal Study. <i>Scientific Reports</i> , <b>2020</b> , 10, 7145	4.9	3
155	Blood and urinary collagen markers in osteoarthritis: markers of tissue turnover and disease activity. <i>Expert Review of Molecular Diagnostics</i> , <b>2020</b> , 20, 57-68	3.8	2
154	Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. <i>Osteoarthritis and Cartilage</i> , <b>2020</b> , 28, 658-668	6.2	13
153	The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 235	5.7	2
152	Bone phenotypes in rheumatology - there is more to bone than just bone. <i>BMC Musculoskeletal Disorders</i> , <b>2020</b> , 21, 789	2.8	7

151	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohnß Disease: A Pilot Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00217	4.2	1
150	Matrix metalloproteinase-degraded type I collagen is associated with variants and preclinical dementia. <i>Neurology: Genetics</i> , <b>2020</b> , 6, e508	3.8	1
149	Dermal fibroblasts have different extracellular matrix profiles induced by TGF-IPDGF and IL-6 in a model for skin fibrosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 17300	4.9	16
148	Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers. <i>BMJ Open</i> , <b>2020</b> , 10, e035	3 101	12
147	The Anti-ADAMTS-5 Nanobody M6495 Protects Cartilage Degradation Ex Vivo. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	13
146	A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis. <i>Scientific Reports</i> , <b>2020</b> , 10, 13541	4.9	3
145	Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2020</b> , 49, 167-168	1.9	7
144	Clinical and biochemical factors associated with risk of total joint replacement and radiographic progression in osteoarthritis: Data from two phase III clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1374-1381	5.3	8
143	Associations between biomarkers of bone and cartilage turnover, gender, pain categories and radiographic severity in knee osteoarthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 203	5.7	19
142	The intestinal tissue homeostasis - the role of extracellular matrix remodeling in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 977-993	4.2	22
141	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 3	2.9	13
140	Osteoarthritis phenotypes and novel therapeutic targets. <i>Biochemical Pharmacology</i> , <b>2019</b> , 165, 41-48	6	84
139	GPDPLQ-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro. <i>Scientific Reports</i> , <b>2019</b> , 9, 3050	4.9	1
138	Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis - a cross-sectional study. <i>Biomarkers</i> , <b>2019</b> , 24, 373-378	2.6	4
137	Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo. <i>Biochemical Pharmacology</i> , <b>2019</b> , 165, 91-98	6	9
136	Bone and Soft Tissue Turnover in Relation to All-cause Mortality in Postmenopausal Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1098-1104	6.4	3
135	Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. <i>Scientific Reports</i> , <b>2019</b> , 9, 11218	4.9	7
134	Incidence of total hip and total knee replacements from the prospective epidemiologic risk factor study: considerations for event driven clinical trial design. <i>BMC Musculoskeletal Disorders</i> , <b>2019</b> , 20, 303	2.8	4

## (2018-2019)

133	Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients. <i>Journal of Proteomics</i> , <b>2019</b> , 208, 103484	3.9	11	
132	An Ex Vivo Tissue Culture Model of Cartilage Remodeling in Bovine Knee Explants. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	2	
131	Recent advances in understanding the phenotypes of osteoarthritis. F1000Research, 2019, 8,	3.6	45	
130	Serological Assessment of the Quality of Wound Healing Processes in Crohnß Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 175-182	1.4	5	
129	IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL-37 and MMP-3. <i>Osteoarthritis and Cartilage</i> , <b>2019</b> , 27, 148-157	6.2	8	
128	Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients. <i>Osteoarthritis and Cartilage</i> , <b>2019</b> , 27, 484-492	6.2	11	
127	Osteoarthritis year in review 2018: biomarkers (biochemical markers). <i>Osteoarthritis and Cartilage</i> , <b>2019</b> , 27, 412-423	6.2	39	
126	Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2019</b> , 27, 611-620	6.2	18	
125	Citrullinated vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study. <i>Biomarkers</i> , <b>2019</b> , 24, 249-254	2.6	7	
124	Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 80-89	5.3	41	
123	Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 173-179	3.9	6	
122	Protein biomarkers associated with pain mechanisms in osteoarthritis. <i>Journal of Proteomics</i> , <b>2019</b> , 190, 55-66	3.9	13	
121	The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFREmAb treatment in rheumatoid arthritis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 73-80	2.2	6	
120	Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 358-366	2.2	6	
119	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1419-1428	9.5	14	
118	Aggrecanase degradation of type III collagen is associated with clinical knee pain. <i>Clinical Biochemistry</i> , <b>2018</b> , 58, 37-43	3.5	10	
117	Development and use of biochemical markers in osteoarthritis: current update. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 121-128	5.3	26	
116	Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development. <i>Drug Discovery Today</i> , <b>2018</b> , 23, 349-358	8.8	13	

115	Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis. <i>Rheumatology</i> , <b>2018</b> , 57, 175-184	3.9	22
114	Identification of pain categories associated with change in pain in patients receiving placebo: data from two phase 3 randomized clinical trials in symptomatic knee osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , <b>2018</b> , 19, 17	2.8	6
113	A Novel High Sensitivity Type II Collagen Blood-Based Biomarker, PRO-C2, for Assessment of Cartilage Formation. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	19
112	Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: A cross-sectional study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207324	3.7	15
111	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , <b>2018</b> , 4, e000648	5.9	3
110	IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study. <i>Clinical and Experimental</i>	2.2	8
109	Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 462-470	2.2	5
108	Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 829-6	8 <del>3.2</del>	11
107	Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients. <i>Osteoarthritis and Cartilage</i> , <b>2017</b> , 25, 866-877	6.2	12
106	Nidogen-1 Degraded by Cathepsin S can be Quantified in Serum and is Associated with Non-Small Cell Lung Cancer. <i>Neoplasia</i> , <b>2017</b> , 19, 271-278	6.4	23
105	Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohnß disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 26-39	6.1	31
104	Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients. <i>Pain</i> , <b>2017</b> , 158, 1254-1263	8	31
103	Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 250	8.5	38
102	Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 705-720	5.3	7
101	Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. <i>Osteoarthritis and Cartilage</i> , <b>2017</b> , 25, 1858-1867	6.2	63
100	A machine learning approach for the identification of new biomarkers for knee osteoarthritis development in overweight and obese women. <i>Osteoarthritis and Cartilage</i> , <b>2017</b> , 25, 2014-2021	6.2	41
99	Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis: the Intensive Diet and Exercise for Arthritis trial (IDEA). Osteoarthritis and Cartilage, 2017, 25, 1822-1828	6.2	26
98	Ulcerative colitis, Crohnß disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohnß disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185855	3.7	27

## (2016-2017)

97	Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 52501-52510	3.3	7	
96	Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rats [corrected]. <i>American Journal of Translational Research (discontinued)</i> , <b>2017</b> , 9, 3517-3527	3	3	
95	Unique insight into microenvironmental changes in colorectal cancer: assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue. <i>Oncology Letters</i> , <b>2017</b> , 13, 3774-3780	2.6	4	
94	Type I and III collagen turnover is increased in axial spondyloarthritis and psoriatic arthritis. Associations with disease activity and diagnostic capacity. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 653-659	2.2	6	
93	Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 13	5.7	22	
92	Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 81	5.7	61	
91	Intercritical circulating levels of neo-epitopes reflecting matrixmetalloprotease-driven degradation as markers of gout and frequent gout attacks. <i>Rheumatology</i> , <b>2016</b> , 55, 1642-6	3.9	3	
90	CRP and a biomarker of type I collagen degradation, C1M, can differentiate anti-inflammatory treatment response in ankylosing spondylitis. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 197-208	2.3	8	
89	Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. <i>Rheumatology International</i> , <b>2016</b> , 36, 541-9	3.6	8	
88	Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. <i>Osteoarthritis and Cartilage</i> , <b>2016</b> , 24, 9-20	6.2	64	
87	Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?. <i>Scandinavian Journal of Rheumatology</i> , <b>2016</b> , 45, 87-98	1.9	35	
86	Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 141	5.7	15	
85	Neo-EpitopesFragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149329	3.7	13	
84	The Need for Predictive, Prognostic, Objective and Complementary Blood-Based Biomarkers in Osteoarthritis (OA). <i>EBioMedicine</i> , <b>2016</b> , 7, 4-6	8.8	18	
83	Abdominal wall hernias-A local manifestation of systemically impaired quality of the extracellular matrix. <i>Surgery</i> , <b>2016</b> , 160, 220-227	3.6	12	
82	Sensitization and Serological Biomarkers in Knee Osteoarthritis Patients With Different Degrees of Synovitis. <i>Clinical Journal of Pain</i> , <b>2016</b> , 32, 841-8	3.5	25	
81	Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives. <i>Annals of Physical and Rehabilitation Medicine</i> , <b>2016</b> , 59, 145-148	3.8	37	
80	Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1348-55	4	9	

79	Quantification of fibronectin as a method to assess ex vivo extracellular matrix remodeling. <i>Biochemical and Biophysical Research Communications</i> , <b>2016</b> , 478, 586-91	3.4	14
78	Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. <i>Osteoarthritis and Cartilage</i> , <b>2016</b> , 24, 2013-2021	6.2	180
77	Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 2402-2409	4.3	48
76	OA phenotypes, rather than disease stage, drive structural progressionidentification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA. <i>Osteoarthritis and Cartilage</i> , <b>2015</b> , 23, 550-8	6.2	40
75	Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. <i>Osteoarthritis and Cartilage</i> , <b>2015</b> , 23, 532-43	6.2	85
74	Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. <i>Chest</i> , <b>2015</b> , 148, 16-23	5.3	19
73	Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2015</b> , 308, G807-30	5.1	156
72	Identifying specific profiles in patients with different degrees of painful knee osteoarthritis based on serological biochemical and mechanistic pain biomarkers: a diagnostic approach based on cluster analysis. <i>Pain</i> , <b>2015</b> , 156, 96-107	8	47
71	Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohnß Disease from Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2015</b> , 9, 863-72	1.5	43
70	Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria. <i>JIMD Reports</i> , <b>2015</b> , 24, 29-37	1.9	10
69	Association between biochemical cartilage markers and clinical symptoms in patients with hip osteoarthritis: cohort study with 2-year follow-up. <i>Osteoarthritis and Cartilage</i> , <b>2015</b> , 23, 57-62	6.2	9
68	Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. <i>Biomarkers</i> , <b>2015</b> , 20, 547-56	2.6	27
67	Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study. <i>Cancer Biomarkers</i> , <b>2015</b> , 15, 783-8	3.8	37
66	The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage explants. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122700	3.7	7
65	Serum cartilage oligomeric matrix protein and development of radiographic and painful knee osteoarthritis. A community-based cohort of middle-aged women. <i>Biomarkers</i> , <b>2015</b> , 20, 557-64	2.6	27
64	The collagen turnover profile is altered in patients with inguinal and incisional hernia. <i>Surgery</i> , <b>2015</b> , 157, 312-21	3.6	37
63	Osteoarthritisa case for personalized health care?. Osteoarthritis and Cartilage, 2014, 22, 7-16	6.2	104
62	Rheumatoid arthritis: a case for personalized health care?. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1273-8	30 <sub>4.7</sub>	19

61	Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover. <i>Osteoarthritis and Cartilage</i> , <b>2014</b> , 22, 44-50	6.2	73
60	Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. <i>Cancer Medicine</i> , <b>2014</b> , 3, 1136-45	4.8	49
59	The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 336-	48 <sup>4</sup>	138
58	The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 93	2.8	67
57	Large scale meta-analysis of urinary C-terminal telopeptide, serum cartilage oligomeric protein and matrix metalloprotease degraded type II collagen and their role in prevalence, incidence and progression of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2014</b> , 22, 683-9	6.2	61
56	Biomarkers of cartilage and surrounding joint tissue. <i>Biomarkers in Medicine</i> , <b>2014</b> , 8, 713-31	2.3	17
55	Meta-analysis identifies loci affecting levels of the potential osteoarthritis biomarkers sCOMP and uCTX-II with genome wide significance. <i>Journal of Medical Genetics</i> , <b>2014</b> , 51, 596-604	5.8	15
54	Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 18789-803	6.3	32
53	Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 3317-26	9.5	65
52	Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 2440-9	9.5	37
51	Type X collagen levels are elevated in serum from human osteoarthritis patients and associated with biomarkers of cartilage degradation and inflammation. <i>BMC Musculoskeletal Disorders</i> , <b>2014</b> , 15, 309	2.8	43
50	Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline. <i>Journal of Clinical Rheumatology</i> , <b>2014</b> , 20, 332-5	1.1	16
49	Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 470-8	5.3	62
48	Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 972-80		48
47	The development and characterization of an ELISA specifically detecting the active form of cathepsin K. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 1601-6	3.5	8
46	Investigation of chondrocyte hypertrophy and cartilage calcification in a full-depth articular cartilage explants model. <i>Rheumatology International</i> , <b>2013</b> , 33, 401-11	3.6	21
45	The development and characterization of a competitive ELISA for measuring active ADAMTS-4 in a bovine cartilage ex vivo model. <i>Matrix Biology</i> , <b>2013</b> , 32, 143-51	11.4	11
44	Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways implications for modern clinical chemistry. <i>Biomarkers</i> , <b>2013</b> , 18, 375-	- <b>8</b> .6	25

43	Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. <i>Future Oncology</i> , <b>2013</b> , 9, 35-44	3.6	5
42	Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. <i>BMC Cancer</i> , <b>2013</b> , 13, 554	4.8	39
41	Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. <i>Assay and Drug Development Technologies</i> , <b>2013</b> , 11, 70-9	2.1 2	185
40	Metabolic health in families enriched for longevity is associated with low prevalence of hand osteoarthritis and influences OA biomarker profiles. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1669-7	4 <sup>2.4</sup>	12
39	Serological identification of fast progressors of structural damage with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2013</b> , 15, R86	5.7	63
38	Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis. <i>Menopause</i> , <b>2013</b> , 20, 578-86	2.5	63
37	Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. <i>PLoS ONE</i> , <b>2013</b> , 8, e54504	3.7	56
36	Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. <i>British Journal of Pharmacology</i> , <b>2012</b> , 167, 151-63	8.6	17
35	Matrix metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 195	8.5	30
34	Future detection and monitoring of diabetes may entail analysis of both Etell function and volume: how markers of Etell loss may assist. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 214	8.5	13
33	IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Seminars in Arthritis and Rheumatism	5.3	62
32	Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. <i>Rheumatology International</i> , <b>2012</b> , 32, 3565-72	3.6	52
31	The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet?. <i>Menopause International</i> , <b>2012</b> , 18, 139-46		34
30	The distribution pattern of critically short telomeres in human osteoarthritic knees. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R12	5.7	30
29	The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage. <i>PLoS ONE</i> , <b>2012</b> , 7, e40081	3.7	4
28	Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 371-9	2.2	28
27	Characterization of an Ex vivo Femoral Head Model Assessed by Markers of Bone and Cartilage Turnover. <i>Cartilage</i> , <b>2011</b> , 2, 265-78	3	12
26	Glucocorticoids exert context-dependent effects on cells of the joint in vitro. Steroids, 2011, 76, 1474-8	22.8	7

#### (2010-2011)

25	Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development. <i>Biomarkers</i> , <b>2011</b> , 16, 193-205	2.6	58
24	Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. <i>BMC Dermatology</i> , <b>2011</b> , 11, 6	2.1	32
23	Molecular serum and urine marker repertoire supporting clinical research on joint diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 859-72	5.3	7
22	Identification of the calcitonin receptor in osteoarthritic chondrocytes. <i>BMC Research Notes</i> , <b>2011</b> , 4, 407	2.3	12
21	A microarray analysis of full depth knee cartilage of ovariectomized rats. <i>BMC Research Notes</i> , <b>2011</b> , 4, 63	2.3	1
20	Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 2548-51	6.3	18
19	Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIMincreased serum CIIM in subjects with severe radiographic osteoarthritis. <i>Clinical Biochemistry</i> , <b>2011</b> , 44, 423-9	3.5	102
18	Biochemical markers of ongoing joint damage in rheumatoid arthritiscurrent and future applications, limitations and opportunities. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, 215	5.7	82
17	Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 460-71	2.9	74
16	Diagnosis of Osteoarthritis by Cartilage Surface Smoothness Quantified Automatically from Knee MRI. <i>Cartilage</i> , <b>2011</b> , 2, 50-9	3	13
15	Serum Markers of Liver Fibrosis: Combining the BIPED Classification and the Neo-Epitope Approach in the Development of New Biomarkers. <i>Disease Markers</i> , <b>2010</b> , 28, 15-28	3.2	28
14	Oral salmon calcitoninpharmacology in osteoporosis. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 1617-29	5.4	37
13	Biochemical markers of joint tissue turnover. Assay and Drug Development Technologies, 2010, 8, 118-24	2.1	19
12	Application of biochemical markers in development of drugs for treatment of osteoarthritis. <i>Biomarkers</i> , <b>2010</b> , 15, 1-19	2.6	30
11	Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo. <i>Biomarkers</i> , <b>2010</b> , 15, 266	- <del>7</del> 6	20
10	Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?. <i>Biomarkers</i> , <b>2010</b> , 15, 195-204	2.6	10
9	Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?. <i>Rheumatology International</i> , <b>2010</b> , 30, 435-42	3.6	97
8	Biochemical markers identify influences on bone and cartilage degradation in osteoarthritisthe effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskeletal Disorders 2010, 11, 125	2.8	55

7	Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. <i>BMC Musculoskeletal Disorders</i> , <b>2010</b> , 11, 62	2.8	34
6	Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markersare they the cause or the consequence of the disease?. <i>Clinical Biochemistry</i> , <b>2010</b> , 43, 793-804	3.5	125
5	Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. <i>Fibrogenesis and Tissue Repair</i> , <b>2010</b> , 3, 5		51
4	Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. <i>Disease Markers</i> , <b>2010</b> , 28, 15-28	3.2	17
3	The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R9	5.7	28
2	Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. <i>Biomarkers</i> , <b>2009</b> , 14, 181-202	2.6	114
1	The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?. <i>Pharmacological Research</i> , <b>2008</b> , 58, 1-7	10.2	124